Demographic and therapy characteristics among the 90 allogeneic recipients
| . | Subjects with TMA (n = 39) . | Subjects without TMA (n = 51) . | P value . |
|---|---|---|---|
| Male gender | 26 (66.7%) | 31 (57.4%) | .66 |
| Age | 8.3 (3.3-13.8) | 6.1 (2.1-15.3) | .54 |
| Race | .26 | ||
| White | 29 (74.4%) | 45 (88.2%) | |
| African American | 7 (18.0%) | 5 (9.8%) | |
| Asian | 1 (2.6%) | 0 (0%) | |
| Other | 2 (5.1%) | 1 (2.0%) | |
| Diagnosis group | .03 | ||
| Malignancy | 6 (15.4%) | 20 (39.2%) | |
| Bone marrow failure | 15 (38.5%) | 9 (17.6%) | |
| Immunodeficiency | 17 (43.5%) | 19 (37.3%) | |
| Genetic/metabolic | 1 (2.6%) | 2 (3.9%) | |
| Benign hematologic disease | 0 (0%) | 1 (2.0%) | |
| Donor type | .81 | ||
| Related | 10 (25.6%) | 15 (27.8%) | |
| Unrelated | 29 (74.4%) | 36 (66.7%) | |
| Stem cell source | <.01 | ||
| Bone marrow | 26 (66.7%) | 44 (86.3%) | |
| Peripheral blood stem cells | 10 (25.6%) | 1 (2.0%) | |
| Cord blood | 3 (7.7%) | 6 (11.8%) | |
| HLA match | |||
| Bone marrow | .5 | ||
| 8/8 | 20/26 (76.9%) | 37/44 (84.1%) | |
| 7/8 | 6/26 (23.1%) | 7/44 (15.9%) | |
| PBSCs | 1.00 | ||
| 8/8 | 6/10 (60.0%) | 1/1 (100%) | |
| 7/8 | 4/10 (40.0%) | 0/1 (0%) | |
| Cord blood | .23 | ||
| 6/6 | 2/3 (66.7%) | 1 (16.7%) | |
| 5/6 | 1/3 (33.3%) | 5 (83.3%) | |
| Conditioning regimen type | .83 | ||
| Myeloablative | 20 (51.3%) | 28 (51.9%) | |
| Reduced Intensity | 19 (48.7%) | 23 (42.6%) | |
| TBI-based regimen | 2 (5.1%) | 10 (19.6%) | .06 |
| GVHD prophylaxis | |||
| CSA + steroids | 24/39 (61.5%) | 27/51 (52.9%) | .67 |
| CSA + methotrexate | 4/39 (10.3%) | 18/51 (35.3%) | .01 |
| CSA+ mycophenolate | 1/39 (2.6%) | 3/51 (5.9%) | .63 |
| CSA + T-cell depletion | 8/39 (20.5%) | 1/51 (2.0%) | .01 |
| Mycophenolate + steroids | 1/39 (2.6%) | 1/51 (2.0%) | 1.00 |
| Tacrolimus or sirolimus | 1/39 (2.6%) | 1/51 (2.0%) | 1.00 |
| . | Subjects with TMA (n = 39) . | Subjects without TMA (n = 51) . | P value . |
|---|---|---|---|
| Male gender | 26 (66.7%) | 31 (57.4%) | .66 |
| Age | 8.3 (3.3-13.8) | 6.1 (2.1-15.3) | .54 |
| Race | .26 | ||
| White | 29 (74.4%) | 45 (88.2%) | |
| African American | 7 (18.0%) | 5 (9.8%) | |
| Asian | 1 (2.6%) | 0 (0%) | |
| Other | 2 (5.1%) | 1 (2.0%) | |
| Diagnosis group | .03 | ||
| Malignancy | 6 (15.4%) | 20 (39.2%) | |
| Bone marrow failure | 15 (38.5%) | 9 (17.6%) | |
| Immunodeficiency | 17 (43.5%) | 19 (37.3%) | |
| Genetic/metabolic | 1 (2.6%) | 2 (3.9%) | |
| Benign hematologic disease | 0 (0%) | 1 (2.0%) | |
| Donor type | .81 | ||
| Related | 10 (25.6%) | 15 (27.8%) | |
| Unrelated | 29 (74.4%) | 36 (66.7%) | |
| Stem cell source | <.01 | ||
| Bone marrow | 26 (66.7%) | 44 (86.3%) | |
| Peripheral blood stem cells | 10 (25.6%) | 1 (2.0%) | |
| Cord blood | 3 (7.7%) | 6 (11.8%) | |
| HLA match | |||
| Bone marrow | .5 | ||
| 8/8 | 20/26 (76.9%) | 37/44 (84.1%) | |
| 7/8 | 6/26 (23.1%) | 7/44 (15.9%) | |
| PBSCs | 1.00 | ||
| 8/8 | 6/10 (60.0%) | 1/1 (100%) | |
| 7/8 | 4/10 (40.0%) | 0/1 (0%) | |
| Cord blood | .23 | ||
| 6/6 | 2/3 (66.7%) | 1 (16.7%) | |
| 5/6 | 1/3 (33.3%) | 5 (83.3%) | |
| Conditioning regimen type | .83 | ||
| Myeloablative | 20 (51.3%) | 28 (51.9%) | |
| Reduced Intensity | 19 (48.7%) | 23 (42.6%) | |
| TBI-based regimen | 2 (5.1%) | 10 (19.6%) | .06 |
| GVHD prophylaxis | |||
| CSA + steroids | 24/39 (61.5%) | 27/51 (52.9%) | .67 |
| CSA + methotrexate | 4/39 (10.3%) | 18/51 (35.3%) | .01 |
| CSA+ mycophenolate | 1/39 (2.6%) | 3/51 (5.9%) | .63 |
| CSA + T-cell depletion | 8/39 (20.5%) | 1/51 (2.0%) | .01 |
| Mycophenolate + steroids | 1/39 (2.6%) | 1/51 (2.0%) | 1.00 |
| Tacrolimus or sirolimus | 1/39 (2.6%) | 1/51 (2.0%) | 1.00 |
Data are shown as median [IQR] or n (%).
TBI, total body irradiation.